文献速递儿童内分泌与遗传代谢儿童神经与发育行为

妊娠期糖尿病二甲双胍与胰岛素治疗与儿童长期生长和发育结局的关联

Association of Long-term Child Growth and Developmental Outcomes With Metformin vs Insulin Treatment for Gestational Diabetes.
PubMed 文献 · JAMA Pediatr · 2019-01-01

该基于新西兰人群的队列研究纳入2005至2012年接受二甲双胍或胰岛素治疗的妊娠期糖尿病孕妇及其子女,链接国家健康数据与B4 School Check评估。调整后,二甲双胍暴露儿童与胰岛素暴露儿童在体重身高z评分、体重身高≥85百分位风险及SDQ得分≥14风险上均无显著差异。结论提示二甲双胍治疗妊娠期糖尿病对学龄前儿童生长和发育结局与胰岛素无显著差别。

要点

  • 二甲双胍与胰岛素治疗GDM的儿童在体重身高z评分上无显著差异。
  • 二甲双胍暴露儿童体重身高≥85百分位的风险与胰岛素暴露儿童相似。
  • 二甲双胍暴露儿童SDQ得分≥14的风险与胰岛素暴露儿童无显著差异。

核心结论

  • 妊娠期糖尿病孕妇使用二甲双胍与胰岛素治疗,其子女在生长和发育评估上无显著差别。

研究设计与样本

  • 基于新西兰国家健康数据的人群队列研究,纳入2005至2012年接受二甲双胍或胰岛素治疗的GDM孕妇及其子女,共3928例妊娠(二甲双胍1996例,胰岛素1932例)。
  • 通过药品索赔数据确定暴露,链接B4 School Check评估儿童生长和SDQ行为发育结局,采用线性回归和对数二项回归及逆概率治疗加权估计关联。

主要发现

  • 调整后,二甲双胍暴露儿童与胰岛素暴露儿童的体重身高z评分平均差异为-0.10(95%CI -0.20至0.01)。
  • 体重身高≥85百分位的调整风险比为0.92(95%CI 0.83-1.02)。
  • 家长报告SDQ得分≥14的调整风险比为1.13(95%CI 0.88-1.46)。

临床怎么用

  • 对于妊娠期糖尿病孕妇,二甲双胍治疗与胰岛素治疗在子女学龄前生长和发育结局上无显著差异,可为临床治疗选择提供参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Metformin is an emerging option for treating gestational diabetes (GDM). However, because metformin crosses the placenta, patients and clinicians are concerned with its long-term effect on child health. OBJECTIVE: To estimate the association of treating GDM with metformin vs insulin with child growth and development. DESIGN, SETTING, AND PARTICIPANTS: Population-based cohort study of New Zealand women treated with metformin or insulin for GDM from 2005 to 2012 and their children. This study linked national health care data to create a cohort of mothers and their children, including data from maternity care, pharmaceutical dispensing, hospitalizations, demographic records, and the B4 School Check (B4SC) preschool health assessment. Women treated pharmacologically with metformin or insulin during pregnancy were included. We excluded pregnancies with evidence of diabetes and deliveries prior to 2013. Liveborn infants were linked to their B4SC results. Data were analyzed between January 2017 and May 2018. EXPOSURES: Pharmacologic treatment for GDM with metformin or insulin, measured using pharmaceutical claims data. MAIN OUTCOMES AND MEASURES: Child growth (weight and height) and Strengths and Difficulties Questionnaire (SDQ) scores for behavioral development. All outcomes were derived from the B4SC screening program. Linear and log-binomial regression with inverse probability of treatment weighting was used to estimate the association of child growth and psychosocial outcomes with metformin vs insulin treatment for GDM. RESULTS: In both treatment groups, the mean (SD) maternal age was 32 (5) years. A large proportion of mothers who were treated with insulin identified as New Zealand European (867 [44.9%]) while 576 mothers who were treated with metformin (28.9%) identified as New Zealand European. Approximately one-third of mothers who were treated with metformin (n = 639) identified as Asian. We identified 3928 pregnancies treated with metformin (n = 1996) or insulin (n = 1932). After adjustment, we observed no meaningful difference in weight for height z scores between children exposed to metformin compared with insulin (mean difference, -0.10; 95% CI, -0.20 to 0.01). Risk of being 85th percentile or greater for weight for height was similar between treatment groups (adjusted risk ratio, 0.92; 95% CI, 0.83-1.02). Mean SDQ scores were not meaningfully different between the treatment groups, Children of metformin-treated mothers were not significantly more likely to have parent-reported SDQ scores of 14 or more (adjusted risk ratio, 1.13; 95% CI, 0.88-1.46) than those of insulin-treated mothers. CONCLUSIONS AND RELEVANCE: Our study compares long-term outcomes among school-aged children following maternal use of metformin vs insulin treatment for GDM. Children of metformin-treated mothers were indistinguishable on growth and developmental assessments from those of insulin-treated mothers. These results will help inform future GDM treatment guidelines.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Landi SN, Radke S, Engel SM, et al. Association of Long-term Child Growth and Developmental Outcomes With Metformin vs Insulin Treatment for Gestational Diabetes. JAMA Pediatr. 2019. PMID: 30508164. doi:10.1001/jamapediatrics.2018.4214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。